MCL1 and prostate carcinoma: Usp9X remains an interesting target as its levels are increased in glioblastoma and this molecule maintains high levels of certain anti-apoptotic factors, such as Mcl-1, Inhibitor of Apoptosis Proteins and a gene fusion observed in 40% of prostatic carcinomas [40].